The beginning of the latest ad from Marc Lichtenfeld’s Lightning Trend Trader is good and juicy, at the very least… how could you not open up the ad and pay attention? “The KILLER Hiding in Your Medicine Cabinet “These Common Drugs Take a Life Every 12 Minutes (Who’s at Risk?) “Here’s the NEW Breakthrough and […]
Articles
Welcome back from vacation, me! There’s no question what ad should be covered first as I brush the sand off my feet and turn up the heat here at Gumshoe HQ… it’s the pitch from Marc Lichtenfeld for his Lightning Trend Trader over at Oxford Club, and the “special report” he’s dangling as bait. That […]
This stock certainly has Gumshoe Nation in a bit of a lather… though it’s also one that many of you already know about, and the solution to this teaser is not super-secret (it has been posted in recent discussions here at Stock Gumshoe a few times). Marc Lichtenfeld puts out a newsletter advisory called Lightning […]
This article originally appeared on July 22, 2015, and the bulk of it has not been updated or revised since. The meat of the ad is essentially the same, and if Lichtenfeld really “bet his paycheck” on this stock (which was and is Alnylam) on July 22 he’s so far lost about 65% of that […]
Marc Lichtenfeld’s trading service that tries to “ride the lightning” by uncovering catalysts that will send stocks soaring. Often covers biotech stocks.
Healthcare-focused newsletter, recommended stocks primarily of emerging device and biotech companies. Was helmed by Marc Lichtenfeld, who moved on to other publications, but stopped publishing after a short while — Lightning Trend Trader, a current publication of Lichtenfeld’s with The Oxford Club, sometimes covers biotech stocks.
Comments
Has anyone had legit success with the lightning trade report?...
I might invest the Catalyst 27-29 pennies I have in my pocket in this and maybe even all the Catalyst 27-29 I keep in a ...
Haven't written about Lichtenfeld's tease, but someone sent it to me today and it's clearly Ligand being touted as this ...
Just reviewed Mark Lichtenfeid's latest video touting a Bio-Tech royalty company. I don't want to spend $1,500.00 to le...